Synmosa Biopharma Corporation

TPEX:4114 Stock Report

Market Cap: NT$14.5b

Synmosa Biopharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 4114?
Owner TypeNumber of SharesOwnership Percentage
Public Companies3,991,2790.95%
Institutions24,242,2125.77%
Private Companies41,816,5249.95%
Individual Insiders45,497,22610.8%
General Public304,699,24672.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 22 shareholders own 27.5% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
6.76%
Formosa Time Pharmaceutical Co., Ltd.
28,394,773NT$979.6m0%no data
4.66%
Zhihui Lin
19,575,209NT$675.3m0%no data
3.34%
The Vanguard Group, Inc.
14,045,843NT$484.6m-0.01%no data
1.97%
Qunhe Investment Co., Ltd.
8,286,142NT$285.9m0%no data
1.92%
Huilan Qiu
8,054,923NT$277.9m0%no data
1.22%
Lephar International Co., Ltd.
5,135,609NT$177.2m0%no data
1.19%
BlackRock, Inc.
4,989,007NT$172.1m0.18%no data
1.02%
Chih-Hui Lin
4,288,283NT$147.9m0%no data
1.01%
You-Peng Zhang
4,230,226NT$145.9m0%no data
0.99%
Dimensional Fund Advisors LP
4,164,983NT$143.7m0.63%no data
0.96%
Li-Wen Huang
4,039,302NT$139.4m0%no data
0.95%
Bora Pharmaceuticals Co., LTD.
3,991,279NT$137.7m0%no data
0.53%
Yu-Yu Lin
2,237,091NT$77.2m0%no data
0.37%
Chien-Jen Wang
1,549,365NT$53.5m0%no data
0.36%
Jia-Xin Zhang
1,518,331NT$52.4m0%no data
0.1%
State Street Global Advisors, Inc.
422,658NT$14.6m-0.94%no data
0.07%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
292,425NT$10.1m0%no data
0.049%
Allianz Global Investors U.S. LLC
206,800NT$7.1m0%no data
0.023%
Eaton Vance Management
97,873NT$3.4m0%no data
0.0034%
HSBC Global Asset Management (UK) Limited
14,477NT$498.7k-21.7%no data
0.0019%
Northern Trust Global Investments
8,146NT$281.3k-54.5%no data
0.0011%
Xiu-Mei Lin
4,496NT$155.1k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 09:37
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Synmosa Biopharma Corporation is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhennan LeeJih Sun Securities Investment Consulting Co., Ltd.
Xiaowei HuangMasterlink Securities Corp.
Yijun ChenSinoPac Securities Investment Service